Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.33 B | -708,982,202 | 2.16 B | 10.08 B | 5.12 B |
| 2022 | 1.35 B | 267.22 M | 2.53 B | 9.52 B | 4.7 B |
| 2021 | 1.31 B | -379,487,170 | 2.21 B | 8.23 B | 4.13 B |
| 2020 | 1.07 B | -283,552,549 | 2.14 B | 7.98 B | 3.59 B |
| 2019 | 1.24 B | 311.13 M | 2.26 B | 8.05 B | 3.73 B |